Mandate

Vinge has advised Egetis Therapeutics in connection with a combined financing comprising an equity private placement and debt financing

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Lorin Arabi and Isabell Bitar (Capital Markets and Public M&A) and of Albert Wållgren, Arvid Weimers and Ida Redander (Banking and finance).

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026